HCV Treatment Recommendations
For treatment-naive adults with chronic hepatitis C without decompensated cirrhosis, use either glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks—both are pangenotypic regimens with >95% cure rates regardless of HCV genotype. 1, 2
Treatment Algorithm for Adults Without Cirrhosis
First-line options (choose one):
- Glecaprevir/pibrentasvir: 8 weeks (treatment-naive, all genotypes)
- Sofosbuvir/velpatasvir: 12 weeks (treatment-naive or treatment-experienced, all genotypes)
Both regimens demonstrate equivalent high efficacy (SVR >95%) in robust clinical trials and real-world cohorts 1. The choice between them can be based on treatment duration preference (8 vs 12 weeks) and cost considerations.
Treatment Algorithm for Adults With Compensated Cirrhosis (Child-Pugh A)
Treatment-naive patients:
- Glecaprevir/pibrentasvir: 8 weeks (all genotypes) OR
- Sofosbuvir/velpatasvir: 12 weeks (all genotypes) 2
Treatment-experienced patients:
- Glecaprevir/pibrentasvir: 12 weeks (all genotypes) OR
- Sofosbuvir/velpatasvir: 12 weeks (all genotypes) 2
Special Considerations for Genotype 3 With Compensated Cirrhosis
Genotype 3 with cirrhosis requires more intensive therapy:
Treatment-naive:
- Sofosbuvir/velpatasvir + weight-based ribavirin (1,000 mg if <75 kg; 1,200 mg if ≥75 kg) for 12 weeks, OR
- Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks, OR
- Glecaprevir/pibrentasvir for 12 weeks 2
Treatment-experienced:
- Sofosbuvir/velpatasvir + ribavirin for 12 weeks, OR
- Sofosbuvir/velpatasvir/voxilaprevir for 12 weeks, OR
- Glecaprevir/pibrentasvir for 16 weeks 2
Pretreatment Evaluation Requirements
Before initiating therapy, assess for:
- Cirrhosis status (determines treatment duration)
- Medication reconciliation for drug-drug interactions
- Laboratory testing: Confirm chronic HCV infection, exclude decompensated liver disease, HBV/HIV coinfection, end-stage renal disease (eGFR <30), and pregnancy 1
Critical Monitoring During Treatment
Diabetes patients: Monitor glucose closely during and after DAA therapy—real-world data show reduced glycemia that can cause symptomatic hypoglycemia. Adjust diabetes medications as needed 1.
Warfarin patients: Monitor INR closely during and after DAA therapy—real-world data show clinically significant reduction in warfarin dose-response. Adjust warfarin dosing to prevent subtherapeutic anticoagulation 1.
Otherwise: On-treatment laboratory monitoring is not required unless side effects occur or adherence concerns arise 1.
Post-Treatment Assessment
Test HCV-RNA and hepatic aminotransferases ≥12 weeks after completing treatment:
- Undetectable HCV-RNA = SVR = virologic cure
- Without cirrhosis and with SVR: No liver-specific follow-up needed
- With ongoing HCV risk factors: Annual HCV-RNA testing and risk-reduction counseling 1
Common Pitfalls to Avoid
Do not use the simplified algorithm for:
- HIV and/or HBV coinfection
- Prior liver transplantation
- Hepatocellular carcinoma
- End-stage renal disease (eGFR <30)
- Current pregnancy
- Decompensated cirrhosis (Child-Pugh B/C)
These populations require specialist management 1.
Decompensated cirrhosis warning: Patients with albumin <35 g/L, MELD ≥14, or genotype 3 have significantly higher risk of hepatic decompensation during DAA treatment and require close monitoring or treatment deferral until after transplantation 3.
Evidence Quality
The recommendations are based on two major 2020 guidelines—AASLD/IDSA 1 and EASL 2—which synthesize multiple robust clinical trials demonstrating safety and high cure rates with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir. Real-world cohort studies confirm these findings translate to clinical practice 1, 4.